Brussels Court Clarifies Requirements In Samsung Patent Win
The Brussels Enterprise Court has held that Samsung Bioepis complied with requirements to waive supplementary patent protection for a biosimilar version of Amgen's osteoporosis treatment Denosumab, rebuffing Amgen's bid to halt...To view the full article, register now.
Already a subscriber? Click here to view full article